Does this sound like trouble????
Press Release Source: NPS Pharmaceuticals, Inc.
NPS Pharmaceuticals to Report Results of PREOS Carcinogenicity Study
Wednesday November 19, 4:30 pm ET
SALT LAKE CITY, Nov. 19 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP - News) announced today that it will report on Thursday, November 20, 2003 at 8:00 a.m. EST (6:00 a.m. MST) preliminary results from a two-year rat carcinogenicity study of PREOS®, its proprietary full-length human parathyroid hormone (PTH) drug candidate being developed for the treatment of osteoporosis. The report will comprise a press release, and a conference call and webcast featuring Dr. Hunter Jackson, Chairman, CEO, and President, and other members of the NPS senior management team.
(Logo: newscom.com )
To participate in the conference call, dial (800) 374-0232 and use confirmation code 4120937. International callers may dial (706) 634-6338, using the same confirmation code. In addition, live audio of the conference call will be simultaneously broadcast over the Internet and may be accessed on the company's web site ( www.npsp.com ). Please click on the webcast link and follow the prompts for registration and access.
If you are unable to participate in the live call, a replay will be available at (800) 642-1687 (with confirmation code 4120937) until midnight, EST, November 27, 2003. International callers may access the replay by dialing (706) 645-9291, using the same confirmation code. The webcast portion of the call will also be available on the NPS website for the same period of time. |
